Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 203 posts found.

Novartis’ Zykadia more effective than chemo, new study shows

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia

Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …

News
roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016
Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …

News
shutterstock_232245868

Novartis’ Zykadia smashes Phase III target for lung cancer

September 23, 2016
Medical Communications, Research and Development Novartis, lung cancer, zykadia

Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …

News
merck_and_co

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

September 7, 2016
Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …

News
pfizer_chrome_plate

Pfizer nabs EU approval for Xalkori for certain lung cancers

August 31, 2016
Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer

The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …

News

Bayer’s liver cancer drug not cost-effective, says NICE

August 19, 2016
Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer

NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …

News

Pfizer’s Xalkori price drop secures NICE recommendation

August 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer

The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …

News
opdivo_1

Shock for BMS as Opdivo misses goal in late-stage lung cancer trial

August 5, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo

Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …

News
merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

News

Scottish regulators back BMS’ Opdivo for lung cancer

July 13, 2016
Research and Development, Sales and Marketing Bristol-Myers Sqibb, NICE, Scottish Medicines Consortium, lung cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE: BMY) said the Scottish Medicines Consortium (SMC) has recommended cancer immunotherapy Opdivo (nivolumab) to treat advanced squamous …

News
msd

MSD gets CHMP positive opinion for keytruda to treat advanced lung cancer

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing CHMP, EMA, MSD, Merck & Co, keytruda, lung cancer

MSD (Merck & Co) said its anti-programmed death-1 (PD-1) therapy, Keytruda (pembrolizumab) to treat lung cancer has secured a positive …

News

Nice rejects AstraZeneca’s Tagrisso for lung cancer in preliminary recommendation

June 24, 2016
Medical Communications, Research and Development AstraZeneca, CDF, NICE, lung cancer, regulation

UK drugmaker AstraZeneca (LSE: AZN) said the National Institute for Health and Care Excellence (Nice) has rejected Tagrisso (osimertinib) to …

News

Nice backs two cancer drugs from Novartis

June 22, 2016
Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …

News

Chi-Med to get $10 million milestone from AstraZeneca after initiation of expanded Phase II trials in NSCLC

June 20, 2016
Research and Development, Sales and Marketing AstraZeneca, Chi-Med, Iressa, Tagrisso, drug trial, lung cancer

Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …

News
merck

Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer

June 17, 2016
Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer

US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025